Literature DB >> 12697851

Adherence to surveillance among patients with superficial bladder cancer.

Deborah Schrag1, Lillian J Hsieh, Farhang Rabbani, Peter B Bach, Harry Herr, Colin B Begg.   

Abstract

BACKGROUND: Patients diagnosed with superficial bladder cancer who have not undergone total cystectomy are at high risk for recurrence, and bladder surveillance with cystoscopy is recommended for such patients every 3-6 months. We examined the degree to which bladder cancer patients undergo the recommended surveillance procedures and identified patient and primary care provider characteristics associated with nonadherence to these recommendations.
METHODS: We used information obtained from the Surveillance, Epidemiology, and End Results (SEER) Program-Medicare-linked database to identify 6717 patients aged 65 years or older who were diagnosed with superficial bladder cancer from 1992 through 1996 and who survived for at least 3 years after diagnosis but did not have a total cystectomy. We used information obtained from Medicare claims forms to examine the frequency with which these patients had a surveillance examination of the bladder during each of five contiguous 6-month intervals from month 7 to month 36 following diagnosis. We examined characteristics of patients and their physicians that were associated with low-intensity surveillance (defined as having an examination during fewer than two of the five possible follow-up intervals). Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two-sided.
RESULTS: Only 40% of the entire cohort had an examination during all five intervals; 1216 patients (18.1%) had low-intensity surveillance. Patient characteristics that were independently associated with low-intensity surveillance were being age 75 years or older (adjusted OR = 1.54, 95% CI = 1.35 to 1.74), nonwhite (adjusted OR = 1.94, 95% CI = 1.57 to 2.40), and having favorable tumor histology (adjusted OR = 0.59, 95% CI = 0.48 to 0.72 for poorly differentiated versus referent well-differentiated tumor grade) and high comorbidity (adjusted OR = 1.72, 95% CI = 1.30 to 2.27). Residence in an urban area or in a census tract with low median income was also associated with low-intensity surveillance.
CONCLUSIONS: The actual practice of surveillance for patients with superficial bladder cancer differs substantially from the standards recommended in clinical guidelines.

Entities:  

Mesh:

Year:  2003        PMID: 12697851     DOI: 10.1093/jnci/95.8.588

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  37 in total

Review 1.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

2.  A plea for a uniform surveillance schedule after radical cystectomy.

Authors:  Guido Dalbagni; Bernard H Bochner; Angel Cronin; Harry W Herr; S Machele Donat
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

3.  Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC).

Authors:  Jean Carlo F Datovo; Wilmar Azal Neto; Gustavo B Mendonça; Danilo L Andrade; Leonardo O Reis
Journal:  World J Urol       Date:  2019-02-25       Impact factor: 4.226

Review 4.  Considerations on the use of diagnostic markers in management of patients with bladder cancer.

Authors:  Piyush K Agarwal; Peter C Black; Ashish M Kamat
Journal:  World J Urol       Date:  2007-12-19       Impact factor: 4.226

5.  Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.

Authors:  Gary H Lyman; Nicole M Kuderer; Stephen J Freedland
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

6.  Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives.

Authors:  Rashid K Sayyid; Abdallah K Sayyid; Zachary Klaassen; Karen Hersey; Hanan Goldberg; Nathan Perlis; Ardalanejaz Ahmad; Ricardo Leao; Thenappan Chandrasekar; Kamel Fadaak; Rabii Madi; Martha K Terris; Antonio Finelli; Robert J Hamilton; Girish S Kulkarni; Alexandre R Zlotta; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2018-02-06       Impact factor: 1.862

7.  In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.

Authors:  Enis Coskuner; Ibrahim Cevik; Alp Ozkan; Ozdal Dillioglugil; Atıf Akdas
Journal:  Int Urol Nephrol       Date:  2012-02-28       Impact factor: 2.370

8.  Correlation of Transabdominal Ultrasonography and Cystoscopy in Follow-up of Patients with Non-muscle Invasive Bladder Cancer.

Authors:  Ahluwalia Puneet; Nair Balagopal; Kumar Ginil; Mathew Georgie; K V Sanjeevan; Thomas Appu
Journal:  Indian J Surg Oncol       Date:  2017-07-21

9.  Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

Authors:  Brent K Hollenbeck; Zaojun Ye; Rodney L Dunn; James E Montie; John D Birkmeyer
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 10.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.